NVE (NVEC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Jun, 2026Executive summary
Annual Meeting scheduled for August 6, 2026, at company headquarters in Eden Prairie, MN.
Shareholders will vote on director elections, executive compensation, and auditor ratification.
Proxy materials include the 2026 Proxy Statement, Letter to Shareholders, and Annual Report on Form 10-K for the year ended March 31, 2026.
Voting matters and shareholder proposals
Election of seven directors is on the agenda.
Advisory vote on named executive officer compensation will be held.
Ratification of Boulay PLLP as independent registered public accounting firm for fiscal year ending March 31, 2027.
Board recommends voting FOR all director nominees and FOR Proposals 2 and 3.
Board of directors and corporate governance
Only shareholders of record as of June 12, 2026, are entitled to vote at the meeting.
Latest events from NVE
- Director elections, executive pay, and auditor ratification headline the 2026 annual meeting.NVEC
Proxy filing22 Jun 2026 - Leadership transitions and robust growth mark a year of expansion and innovation.NVEC
Proxy filing22 Jun 2026 - Board expansion, executive pay, and auditor ratification headline the August 2026 proxy.NVEC
Proxy filing22 Jun 2026 - Quarterly net income rose 27% year-over-year, driven by strong product sales and margin gains.NVEC
Q4 20267 May 2026 - Quarterly revenue up 23% and net income up 11%, with a $1.00 dividend announced.NVEC
Q3 202614 Apr 2026 - Revenue and net income declined, but gross margin and cash returns to shareholders remained strong.NVEC
Q1 20253 Feb 2026 - Gross margin rose to 86% as R&D revenue surged and a $1.00 dividend was declared.NVEC
Q2 202519 Jan 2026 - Revenue and net income fell, but gross margin improved to 84% and a dividend was declared.NVEC
Q3 20259 Jan 2026 - Maintained strong earnings, expanded R&D, and appointed a new director with medical expertise.NVEC
Proxy Filing1 Dec 2025